Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.4M 2.25M 2.05M 3.86M 264M 3.92M 26.48M 10.35M 132M 10.41M 10.19M 442M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.6M 8.06M 7.35M 13.82M 947M 14.03M 94.77M 37.05M 474M 37.27M 36.46M 1.58B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 77 30/11/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
+0.74%+35.83%+10.24%+503.12% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.27%+1.48%-15.73%-12.94% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
+0.07%-9.33%+35.47%+139.01% 12.72B
Average +0.30%+9.21%+58.81%+203.66% 29.64B
Weighted average by Cap. +0.30%+10.12%+56.56%+167.57%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.97 0.1 0.7 0.27 3.49 0.27 0.27 11.64 0.14 0.12 0.11 0.1 0.19 12.91 0.19 1.29 0.51 6.46 0.51 0.5 21.55
Net income -3.1M -2.69M -2.52M -2.3M -4.32M -296M -4.39M -29.64M -11.59M -148M -11.66M -11.4M -494M -18.47M -16.01M -15M -13.68M -25.72M -1.76B -26.11M -176M -68.95M -882M -69.37M -67.86M -2.94B
Net Debt 7.1M 6.15M 5.76M 5.25M 9.88M 677M 10.03M 67.74M 26.48M 339M 26.64M 26.06M 1.13B 7.15M 6.2M 5.81M 5.3M 9.96M 682M 10.11M 68.3M 26.7M 342M 26.86M 26.27M 1.14B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-